We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.
Home Carousel
FACIT leads seed round in Nanology Labs
Ontario start-up to commercialize smart nanomedicine technology for brain cancer
FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.
FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies
Notch is a Canadian biotech incubated by Ontario-based Centre for Commercialization of Regenerative Medicine (CCRM)
The financing is one of the largest Series A financing round in Canadian biotech history, notably at a time of heightened interest by Ontario in commercializing homegrown intellectual property.
FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology
Showcasing Ontario’s emerging biotech entrepreneurs and driving value from intellectual property
FACIT's Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.
FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario
Blend of scientific, industry, investment and entrepreneurial expertise complements FACIT’s leading role in growing Ontario’s life sciences commercialization
Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures.
FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund
Ontario First capital supports early stage commercialization of cancer intellectual property
The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.
FACIT Features: Triphase Accelerator reports positive interim results of lead compound in Phase 1 Clinical Trial for Lymphoma
The encouraging study results includes six complete remissions in previously-treated lymphoma patients.
FACIT congratulates Triphase Accelerator on interim results from its ongoing Phase 1 multi-center, open-label monotherapy study of TRPH-222.
as of February 2021
-
$1.3B
Leveraged funding associated with FACIT support.
-
$44M
Funding & equity investments.
-
62
Projects at Ontario institutions or Startups supported by FACIT funding.
-
16
Companies in Ontario created by FACIT investments.
Our Strategic Partner
FACIT also facilitates technology transfer, partnerships, and collaborations with the
Ontario Institute for Cancer Research >
